Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Bifidobacterium→

Bifidobacterium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
Not available
Drug class
Probiotic bacterial genuslive microbial biotherapeutic ingredient
Mechanism of action
May contribute to gut microbial community function, fermentation of carbohydrates and production of short-chain fatty acids. Clinical effects are strain-specific and cannot be generalised from the genus name alone.
Indications / reported uses
  • Use in selected probiotic products for gastrointestinal health or prevention of antibiotic-associated diarrhoea where supported by the specific strain and product authorisation; no single therapeutic indication can be assigned to all Bifidobacterium species or strains

Sources: NIH NCCIH — Probiotics: what you need to know · PubMed — Bifidobacterium strain-specific clinical evidence · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Bifidobacterium Environmental Risk Assessment (ERA) (the Bifidobacterium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.